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Abstract
Introduction: Cutaneous adverse drug reactions (CADRs) are the most common adverse drug reactions
reported in the literature. CADRs have resulted in disabling infirmities during hospitalization and
complications following outdoor drug therapy. The pattern of CADRs and the responsible drugs usually
changes with the introduction of newer drugs and evolving clinical practices. Moreover, several international
studies showed variable prevalence, emphasizing the need for local data in light of different socioeconomic
and demographic practices. Therefore, the purpose of this study is to evaluate the prevalence of adverse
cutaneous drug reactions and identify the clinical spectrum and any potential risk factors.
Methodology: The current study is a descriptive cross-sectional study conducted at Aga Khan University
Hospital, Pakistan. One hundred ninety-three patients who met the study inclusion criteria were included.
Data were collected from patients on a proforma after taking informed consent. Quantitative data were
presented as simple descriptive statistics giving mean and standard deviation, while qualitative variables
were presented as frequency and percentages. Effect modifiers were controlled through stratification to
highlight the effect of these on the outcome variable. The post-stratification chi-square test was applied and
the p-value of ≤0.05 was statistically significant.
Results: A total of 193 patients who had cutaneous adverse drug reactions were included in the study. The
mean age in this study was 47.78±8.33 years. One hundred eight (56%) were male and 85 (44%) were female.
Out of 193 patients, 135 (69.9%), 50 (25.9%), 24 (12.4%), 12 (6.2%), 20 (10.4%), 11 (5.7%) and six (3.1%) had
maculopapular rash, acneiform eruptions, Stevens-Johnson syndrome, erythema multiform, urticaria, fixed
drug eruptions and toxic epidermal necrolysis, respectively.
Conclusion: CADRs are a common clinical presentation and awareness and knowledge about their diagnosis
and prevention is important. It can be assumed that in our local setup, the clinical trends and medications
causing ADRs are strikingly similar to those found in other countries. Physicians commonly come across
these cases and they should be well aware of the clinical spectrum of skin reactions to enable early diagnosis
and management. 
Categories: Dermatology, Internal Medicine, Allergy/Immunology
Keywords: cutaneous adverse drug reaction, incidence, age, gender, smoking, socioeconomic status
Introduction
Cutaneous adverse drug reactions (CADRs) are the most common adverse drug reactions reported in the
literature [1]. Studies have found the overall incidence of CADRs in developed countries as 1-3%, while the
incidence in developing countries is reported to be between 2% to 5% [2]. A wide spectrum of cutaneous
manifestations ranging from maculopapular rashes to toxic epidermal necrolysis (TEN) can be caused by
different drugs [3]. CADRs have resulted in disabling infirmities during hospitalization and complications
following outdoor drug therapy [4]. Certain patient groups seem to be at increased risk of developing such
cutaneous drug reactions [5]. The incidence of developing a cutaneous reaction increases with the number of
drugs administered [6]. 
Awareness about the culprit drugs can help physicians to choose safer medicines [7]. The Naranjo Scale is a
specific questionnaire designed for determining the likelihood of probability and is assigned through a score
that is termed as definite, probable, possible, and doubtful [8]. The pattern of drug reactions and the
offending drugs show changing trends with the introduction of newer drugs. The reactions can mimic viral
exanthems, neoplastic diseases, or collagen vascular diseases [9]. Although these types of cutaneous
eruptions are common and complete information about their incidence, severity, complications and ultimate
health effects are still unavailable because most of these cases are usually remain unreported [10].
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Dermatologists and physicians usually come across many cases of suspected CADRs. Therefore, they should
be familiar with different types of skin reactions to enable early diagnosis and prompt withdrawal of the
causative drugs to prevent morbidity and mortality [11]. The pattern of CADRs and the responsible drugs
usually change with the introduction of newer drugs and evolving clinical practices. Moreover, several
international studies showed variable prevalence, emphasizing the need for local data in light of different
socioeconomic, demographic, and prescription practices. Therefore, the purpose of this study is to evaluate
the prevalence of patients who present with adverse cutaneous drug reactions and also to identify the
clinical spectrum and potential risk factors. Currently, there is no local published data available that
evaluate these reported cutaneous adverse drug reactions. The incidence and the pattern of the clinical
spectrum from this study would give a better understanding of CADRs that would be helpful for local
healthcare providers to devise effective management plans for such patients. 
Materials And Methods
A descriptive cross-sectional study was conducted at the dermatology outpatient department, Aga Khan
University Hospital, Pakistan. The study duration was six months after approval from the ethical review
committee (March 2017 to September 2017). The study objectives were to determine the frequency of the
clinical spectrum of CADRs and risk factors in patients presenting at a tertiary care hospital, Karachi. The
required sample size was 193 using the WHO software, taking the least prevalence of 4.4%, confidence level
[CI]=95% and margin of error equal to 2.9%. Patients of all ages and both sexes presenting with cutaneous
adverse drug reactions were included. Patients with chronic cutaneous and systemic disorders, using
multiple drugs, and who were not willing to participate were excluded. The CADRs were assessed for their
causality by performing the Naranjo’s algorithm scale [10], and CADRs were graded as highly probable,
possible, and definite according to the scale. Informed consent was obtained from all the participants. A
detailed history regarding drug intake, cutaneous eruptions, associated systemic symptoms, the time gap
between drug intake and skin eruption, duration, and the indication was recorded. A detailed general
physical examination, cutaneous examination regarding morphology, pattern, and distribution of eruption
was performed. The findings of quantitative variables (age, reaction time, and duration of cutaneous
adverse drug reaction) and qualitative variable (gender, socioeconomic, occupation, marital, educational and
smoking status, family history, and duration of cutaneous adverse drug reaction was entered in proforma
(Figure 1). As basic descriptive statistics, quantitative data was presented giving mean and standard
deviation, and qualitative variables were presented as frequency and percentages. To see the influence of
these on the outcome variable, effect modifiers were regulated by stratification. To take a p-value of ≤0.05 as
significant, the post-stratification chi-square test was applied.
FIGURE 1: Relation of frequency of cutaneous adverse drug reactions
(CADRs) with age. n=193
Results
One hundred ninety-three patients were enrolled in the study period in which 108 patients (56%) were male
and 85 (44%) were female. The mean age of the patients was 47.78±8.33 years. (Figure 1). The duration of
adverse drug reactions between drug ingestion and the onset of eruption ranged from less than a day to
more than one day. The maculopapular eruption was found to be the most common reaction observed in 135
(69.9%) patients. Out of those, 85 (63%) patients developed adverse drug reactions in less than 24 hours
while 50 (37%) patients developed reactions after 24 hours. Fifty (25.9%) cases were of acneiform eruption,
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24 (12.4%) were of Stevens-Johnson syndrome (SJS), 12 (6.2%) cases were of erythema multiform (EM), 20
(10.4%) cases were of urticaria, 11 (5.7%) cases were of fixed drug reaction (FDE) (Figure 2, A) and six (3.1%)
were of toxic epidermal necrolysis (TEN) (Figure 2, B&C); 75% of patients with urticaria, EM, and SJS had
CADRs in <1 day as compared to FDE which showed the reaction in >1 day in 45.5% of patients. The
frequency of CADRs in TEN patients was the same for both as 50% of patients showed adverse drug reaction
in <1 day and 50% showed in >1 day (Figure 3).
FIGURE 2: A. Fixed drug eruption on limb. B & C, Toxic epidermal
necrolysis showing crusting and peeling of skin
FIGURE 3: Frequency and Duration of Cutaneous Adverse Drug
Reactions
The prevalence of maculopapular rashes was greater in males (73, 54.1%) than in (62, 45.9%) females but
there was no association found between maculopapular rash and gender, age, socioeconomic, occupational,
marital, and educational status. The results showed a significant association between erythema multiform
and SJS with gender and socio-economic status. Furthermore, a correlation was found between marital
status and urticaria, while acneiform eruption had a significant relationship with educational status and
family history. No such association was found between selected adverse drug reactions with smoking and age
(Table 1). Causality assessment as per the Naranjo algorithm showed that 82 CADRs were probable, 48 were















Male  73 (54.1) 13 (65) 05 (45.5%) 27 (54) 18 (75) 10(83.3) 03 (50)
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Female 62 (45.9) 07 (35) 06 (54.5) 23 (46) 06 (25) 02(16.7) 03 (50)
P-value 0.26 0.43 0.26 0.33 0.04 0.03 0.54
    Socioeconomic
Status
Lower 07 (5.2) 02 (10) 00 (00) 03 (6) 00 (00) 00 (00) 00 (00)
Lower
Middle 14 (10.4) 01 (5) 00 (00) 04 (8)
03
(12.5) 03 (25) 02 (33.3)
Middle 26 (19.3) 03 (15) 02 (18.2) 08 (16) 00 (00) 00 (00) 00 (00)
Upper





Upper 49 (36.3) 08 (40) 05 (45.5) 18 (36) 07(29.2) 01 (8.3) 02 (33.3)
P-value 0.31 0.90 0.78 0.69 0.00 0.00 0.37
Occupational Status
Employed 99 (73.3) 14 (70) 06 (54.5) 41 (82) 16(66.7) 09 (75) 05 (83.3)
Unemployed 36 (26.7) 06 (30) 05 (45.5) 09 (18) 08(33.3) 03 (25) 01 (16.7)
P-value 0.08 0.02 0.60 0.20 0.48 0.43 0.41
Marital Status
Married 113 (83.7) 20 (100) 09 (81.8) 43 (86) 21(87.5)
11
(91.7) 06 (100)
Unmarried 22 (16.3) 00 (00) 02 (18.2) 07 (14) 03(12.5) 01 (8.3) 00 (00)
P-value 0.51 0.37 0.02 0.57 0.37 0.40 0.33
Educational Status
Illiterate 08 (5.9) 01 (5) 01 (9.1) 01 (2) 01 (4.2) 02(16.7) 01 (16.7)
Primary 24 (17.8) 04 (20) 01 (9.1) 06 (12) 04(16.7)
02
(16.7) 00 (00)
Secondary 36 (26.7) 02 (10) 04 (36.4) 07 (14) 05(20.8)
02
(16.7) 01 (16.7)
Higher 67 (49.6) 13 (65) 05 (45.5) 36 (72) 14(58.3) 06 (50) 04 (66.7)
P-value 0.25 0.00 0.18 0.89 0.37 0.63 0.40
  Smoking Status
Smoker 84 (62.2) 15 (75) 06 (54.5) 33 (66) 18 (75) 09 (75) 03 (50)
Non-smoker 51 (37.8) 05 (25) 05 (45.5) 17 (34) 06 (25) 03 (25) 03 (50)
P-value 0.23 0.45 0.21 0.34 0.32 0.17 0.36
Family History
Yes 23 (17) 03 (15) 01 (9.1) 12 (24) 05(20.8)
02
(16.7) 01 (16.7)
No 112 (83) 17 (85) 10 (90.9) 38 (76) 19(79.2)
10
(83.3) 05 (83.3)
P-value 0.26 0.04 0.62 0.46 0.58 0.30 0.64
TABLE 1: Socio-demographic representation of cutaneous adverse drug reactions (CADRs) with
different variables. n=193
FDE (fixed drug eruption), SJS (Stevens-Johnson Syndrome), TEN (Toxic Epidermal Necrolysis), EM (Erythema Multiforme)
Discussion
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Drug reactions are adverse reactions of the body that occur after the drug administration and are not
characteristic of the targeted pharmacodynamics impact. The pattern of drug reactions and offending drugs
indicates evolving patterns with the advent of newer drugs. Drug reactions are mostly poorly reported and
many queries regarding pathogenesis still have to be addressed. Cutaneous drug reactions are one of the
most prevalent forms of drug reaction [12]. In developing countries, the prevalence of CADRs varies from 1%
to 3% among patients, whereas some studies reported up to 2% to 5% of the inpatients. However, there is a
lack of comprehensive data about the clinical spectrum of drug rashes [13]. The inadequacy of data could be
attributed to reasons such as diagnostic dilemmas and lack of awareness and resources. 
In this study, the males were more prevalent with CADRs than females, which was in accordance with two
other studies conducted by Suthar and Desai and Sharma et al. [2,14]. Most of the patients were in the range
of 51-60 years (39.36%) followed by 41-50 years (32.12%), which is comparable with other research results
which established similar observations. Their analysis demonstrates that adults between the ages of 20-49
were at the highest risk of drug reactions [15].
In the current study, the most common CADR was maculopapular rash, which accounted for the overall
69.9%. Garg and John in 2015 had a similar finding where maculopapular rash was the commonest type of
CADR (48.8%) [16]. The second most common form of CADR in this study was acneiform eruption (25.91%),
although in other studies it was reported in 11.3% of patients, similarly one of the studies also observed this
in 1.5% to 7.5% [14-17]. This difference may be attributed to the different ways of drug usage and different
feature of an ethnic group. Moreover, one of the studies by Ding and Lee [8] reported 28.1% cases were SJS,
5.7% were TEN, 5.3% were urticaria/angioedema and (5.3%) were FDE, which was similar to our finding. In
this study, the time intervals during which manifestations appear (lag time) have been recorded.
Maculopapular rash, acneiform, SJS, and urticaria were those patterns observed in the patients within 24
hours. This was comparable with other published studies, which reported the mean reaction time of urticaria
was 10 hours followed by 21.70 hours of FDE, the mean lag time for urticaria was 35.27 hours, 3.66 days for
TEN, and 3.69 days for SJS respectively. As compared to our results, a study by Agrawal and Ghate showed
slightly different results of the lag phase of maculopapular rash, acneiform, and EM which took around 5.66,
10, and 5.7 days [18].
Our results show that there is a significant relationship between EM and SJS with gender and
socioeconomic. Some studies have demonstrated similar results [19-20]. One of the implications of this
study was to focus on acneiform eruption and occupation, the current study results were statistically
significant and few previous studies highlighted a similar significant relationship [21-22]. A positive
background of the family history with acneiform eruption can be the predictor of CADR and the current
study highlights the same relationship [23]. Moreover, a strong statistical relationship was found between
acneiform and education, which shows that inadequate knowledge and the impact of false myths have a
significant impact on the development of acneiform eruption [24]. In our study, the majority of the patients
were smokers but none of the patterns of CADRs show a possible significant correlation with smoking habits
and this trend has also been noticed by Vijendera in his study [25]. As compared to the unmarried
population, the married population shows a high prevalence of urticaria, and an association was found
between marital status and urticaria. Similar results were reported by Lindegard that they also found a
statistical correlation between marital status and urticaria and also their married women show more
prevalent to urticaria than un-married [26].
The current study highlighted the prevalence of the clinical spectrum of CADR and more studies need to be
conducted in the future to assess the magnitude of CADRs in local setups. Besides, long-term patient
monitoring and follow-up could not be done in our study. Despite these limitations, the study shows that
health care providers should realize the importance of reporting every drug reaction. Due to the emergence
of newer drugs, the patterns of CADRs are changing every year. Physicians should have adequate knowledge
of ADRs, especially of newer drugs to minimize such events and manage them effectively.
Conclusions
In dermatology practice, CADRs are a significant clinical entity, and the severity of these drug reactions
usually range from mild maculopapular rashes to fatal eruptions like TEN. Cutaneous drug eruptions are
caused by a wide variety of agents and these are among the most frequently reported adverse reactions.
These drug reactions are responsible for around 3% of all outdoor and hospitalize patients. Dermatologists
and primary care physicians regularly come across such cases and they should be aware of the spectrum of
skin reactions to enable early diagnosis, withdrawal of the drugs, and management accordingly. 
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